
Evidence analysis
With the new shift in the U.S. Congress, time is running out on bills targeting drug patents
What is established A set of bipartisan bills aimed at reforming drug patent laws in the United States is facing a critical deadline before the new Congress convenes in January 2027. These bills seek to address strategies used…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Zybrivo, sintilimab, Status: Opinion
What is established Zybrivo (sintilimab) is a new medicine evaluated by the European Medicines Agency (EMA) for human use. It is an immune checkpoint inhibitor designed to target programmed death-1 (PD-1) receptors, which play a role in regulating…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opinion
Health & Science Evidence Dossier: Ruxolitinib Krka What is established Ruxolitinib is a protein kinase inhibitor targeting Janus-associated kinases (JAKs), enzymes involved in signaling pathways important for blood cell production and immune regulation. The original branded version, Jakavi,…
Read →
Evidence analysis
Targeted signal management (TSM) procedure on phenobarbital – final translations of the product information text into EU languages
What is established The European Medicines Agency (EMA) has completed a targeted signal management (TSM) procedure concerning phenobarbital, a long-standing medication used primarily for epilepsy and seizures. The most recent documentation finalizes translations of the updated product information…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Spevigo, spesolimab, Date of authorisation: 09/12/2022, Revision: 6, Status: Authorised
What is established Spevigo (active substance spesolimab) is a medicine authorized in the European Union for the prevention and treatment of flare-ups of generalised pustular psoriasis (GPP), an inflammatory skin disease characterized by widespread pustules. It is approved…
Read →
Evidence analysis
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026
CHMP November 2026 Meeting: New Medicine Recommendations and Therapeutic Extensions In November 2026, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) conducted its regular meeting and issued a series of recommendations concerning new medicines…
Read →
Evidence analysis
Buro Media Launches Database of Lukashenko’s Inner Circle
Database of Inner Circle Around Belarusian Leader Lukashenko On November 13, 2026, Buro Media, the Belarusian member center affiliated with the Organized Crime and Corruption Reporting Project (OCCRP), launched a database titled “Favorites.” This resource profiles 20 individuals…
Read →
Evidence analysis
Five Questions About the Future of Global Anticorruption Efforts in the Trump Era
Accountability in Global Anticorruption Efforts: An Evidence Review What is established Corruption remains a significant obstacle to economic development and governance globally. Over recent decades, a network of transnational anti-bribery laws and enforcement mechanisms has emerged, primarily influenced…
Read →
Evidence analysis
Indonesia: Alleged Excessive Force Against Protesters
Indonesia: Allegations of Excessive Force Against Protesters on National Heroes’ Day 2026 What is established On November 10, 2026, youth protests took place in several Indonesian cities, including Yogyakarta on Java Island. The demonstrations addressed concerns such as…
Read →
Evidence analysis
France: Sweeping Bill Threatens Peaceful Protest, Rights
Work & Wages: France’s Proposed Protest Law and Its Broader Impact What is established In late October 2026, the French Senate passed a draft law in its first reading aimed mainly at addressing violent disorder linked to protests.…
Read →